About Gamma-interferon-inducible lysosomal thiol reductase
Gamma-interferon-inducible lysosomal thiol reductase (IFI30) is a protein
from Homo sapiens identified by UniProt accession
P13284, 250 residues long.
MolForge cross-references it against 0 known binders and
103 disease associations.
Target properties
| Protein name | Gamma-interferon-inducible lysosomal thiol reductase |
|---|
| UniProt accession | P13284 |
|---|
| Gene | IFI30 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 250 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (103)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.45
- blood protein measurement · score 0.32
- basophil count · score 0.30
- monocyte percentage of leukocytes · score 0.28
- cathepsin L1 measurement · score 0.28
- alkaline phosphatase measurement · score 0.26
- BMI-adjusted waist-hip ratio · score 0.25
- basophil percentage of leukocytes · score 0.25
- multiple sclerosis · score 0.24
- C-reactive protein measurement · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P13284-F1 | alphafold | PREDICTED | 83.23 | — |
Amino-acid sequence (250 residues)
MTLSPLLLFL PPLLLLLDVP TAAVQASPLQ ALDFFGNGPP VNYKTGNLYL RGPLKKSNAP LVNVTLYYEA LCGGCRAFLI RELFPTWLLV MEILNVTLVP YGNAQEQNVS GRWEFKCQHG EEECKFNKVE ACVLDELDME LAFLTIVCME EFEDMERSLP LCLQLYAPGL SPDTIMECAM GDRGMQLMHA NAQRTDALQP PHEYVPWVTV NGKPLEDQTQ LLTLVCQLYQ GKKPDVCPSS TSSLRSVCFK
Explore Gamma-interferon-inducible lysosomal thiol reductase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets